Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus

J Mol Med (Berl). 2019 Nov;97(11):1567-1574. doi: 10.1007/s00109-019-01837-2. Epub 2019 Oct 31.

Abstract

Status epilepticus (SE) is a life-threatening condition characterized by ongoing seizure activity which can lead to severe brain damage and death if not treated properly. Recent work suggests that alterations in blood-brain barrier (BBB) function and subsequent cortical exposure to coagulation factors may initiate, promote, and/or sustain SE. This suggestion is based on the observation that the serine protease thrombin, which plays a fundamental role in the blood coagulation cascade, increases neural excitability through the activation of protease-activated receptor 1 (PAR1). However, it remains unclear whether systemic inhibition of thrombin asserts "anti-epileptic" effects in vivo. We here used the pilocarpine model of SE in adult 3-month-old male mice to address the question whether intraperitoneal injection of the thrombin inhibitor α-NAPAP (0.75 mg/kg) counters SE. Indeed, pharmacological inhibition of thrombin ameliorates the behavioral outcome of pilocarpine-induced SE. Similar results are obtained when the thrombin receptor PAR1 is pharmacologically blocked using intraperitoneal injection of SCH79797 (25 μg/kg) prior to SE induction. Consistent with these results, an increase in thrombin immunofluorescence is detected in the hippocampus of pilocarpine-treated animals. Moreover, increased hippocampal serine protease activity is detected 90 min after SE induction, which is not observed in animals treated with α-NAPAP prior to SE induction. Together, these results corroborate and extend recent studies suggesting that novel oral anticoagulants which target thrombin (and PAR1) may assert anti-epileptic effects in vivo. KEY MESSAGES: Systemic thrombin/PAR1-inhibition ameliorates anticoagulants behavioral seizures. Status epilepticus increases thrombin levels in the hippocampus. Increased serine protease activity in the hippocampus after status epileptic. Anti-epileptic potential of clinically used anticoagulants must be evaluated.

Keywords: Blood-brain barrier; Hippocampus; Protease-activated receptor 1; Status epilepticus; Thrombin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticoagulants / therapeutic use
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Male
  • Mice
  • Pilocarpine / toxicity*
  • Pyrroles / therapeutic use
  • Quinazolines / therapeutic use
  • Receptor, PAR-1 / metabolism*
  • Status Epilepticus / chemically induced*
  • Thrombin / antagonists & inhibitors*
  • Thrombin / metabolism*

Substances

  • Anticoagulants
  • N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine
  • Pyrroles
  • Quinazolines
  • Receptor, PAR-1
  • Pilocarpine
  • Thrombin